2 Spam-Free Article(s) Found
https://www.zacks.com/stock/news/2267310/moderna-mrna-q1-earnings-beat-estimates-revenues-down-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2267310
May 02, 2024 - Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
zc:-479365274755264031
0
https://www.zacks.com/stock/news/2264391/moderna-mrna-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2264391
Apr 29, 2024 - Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
zc:248949341476254570
0